erial

  1. T

    Genetically Modified 'Serial Killer' T Cells Obliterate Tumors In Leukemia Patients

    In a cancer treatment breakthrough 20 years in the making, researchers from the University of Pennsylvania's Abramson Cancer Center and Perelman School of Medicine have shown sustained remissions of up to a year among a small group of advanced chronic lymphocytic leukemia (CLL) patients treated...
Back
Top